CN104011046B - 氨基嘧啶激酶抑制剂 - Google Patents
氨基嘧啶激酶抑制剂 Download PDFInfo
- Publication number
- CN104011046B CN104011046B CN201280053781.XA CN201280053781A CN104011046B CN 104011046 B CN104011046 B CN 104011046B CN 201280053781 A CN201280053781 A CN 201280053781A CN 104011046 B CN104011046 B CN 104011046B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- aryl
- substituent group
- heteroatomic
- perfluor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*P(N*)(OC)=O Chemical compound C*P(N*)(OC)=O 0.000 description 6
- NGPHIHBCUFLDDQ-HZCBDIJESA-O CC(NC(SCCc1ccnc(N[C@H](CC2)CC[C@@H]2NCc2ccc(cc(cc3)[OH2+])c3c2)n1)=O)=O Chemical compound CC(NC(SCCc1ccnc(N[C@H](CC2)CC[C@@H]2NCc2ccc(cc(cc3)[OH2+])c3c2)n1)=O)=O NGPHIHBCUFLDDQ-HZCBDIJESA-O 0.000 description 1
- JAMMJFIMBUCUNH-KCCRSXOISA-O CC(OC(C(C1)C(CN(Cc2nc(-c3c[s]cc3)ccc2)O)CC[C@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1)[OH2+])=O Chemical compound CC(OC(C(C1)C(CN(Cc2nc(-c3c[s]cc3)ccc2)O)CC[C@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1)[OH2+])=O JAMMJFIMBUCUNH-KCCRSXOISA-O 0.000 description 1
- LGSGIWBAKCYGBB-UHFFFAOYSA-N CC1C(C2)C2CCC1 Chemical compound CC1C(C2)C2CCC1 LGSGIWBAKCYGBB-UHFFFAOYSA-N 0.000 description 1
- UIPRAKLJIRRXKU-XYPYZODXSA-N COCCOCCN[C@H](CC1)CC[C@@H]1N Chemical compound COCCOCCN[C@H](CC1)CC[C@@H]1N UIPRAKLJIRRXKU-XYPYZODXSA-N 0.000 description 1
- OZLKYWUOMZONBR-ZSOIEALJSA-N CS/C(/C(NC=O)=O)=C\Cc1ccnc(Nc2ccccc2)n1 Chemical compound CS/C(/C(NC=O)=O)=C\Cc1ccnc(Nc2ccccc2)n1 OZLKYWUOMZONBR-ZSOIEALJSA-N 0.000 description 1
- ZNCCSWMUWLFPBI-RITGAEKQSA-N NC[C@@H](CCC1)CC[C@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1 Chemical compound NC[C@@H](CCC1)CC[C@H]1Nc1nc(/C=C(/C(N2)=O)\SC2=O)ccn1 ZNCCSWMUWLFPBI-RITGAEKQSA-N 0.000 description 1
- FQGGTIFOJIOPFG-JBLHJTENSA-N O=C(/C(/S1)=C/c2nc(N[C@H](CC3)CC[C@@H]3NCc3c(cccc4)c4ccc3)ncc2)NC1=O Chemical compound O=C(/C(/S1)=C/c2nc(N[C@H](CC3)CC[C@@H]3NCc3c(cccc4)c4ccc3)ncc2)NC1=O FQGGTIFOJIOPFG-JBLHJTENSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555617P | 2011-11-04 | 2011-11-04 | |
| US61/555617 | 2011-11-04 | ||
| PCT/US2012/061597 WO2013066684A1 (en) | 2011-11-04 | 2012-10-24 | Aminopyrimidine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104011046A CN104011046A (zh) | 2014-08-27 |
| CN104011046B true CN104011046B (zh) | 2017-05-03 |
Family
ID=47116510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280053781.XA Expired - Fee Related CN104011046B (zh) | 2011-11-04 | 2012-10-24 | 氨基嘧啶激酶抑制剂 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8927525B2 (enExample) |
| EP (1) | EP2776432B1 (enExample) |
| JP (1) | JP6215832B2 (enExample) |
| KR (1) | KR101990605B1 (enExample) |
| CN (1) | CN104011046B (enExample) |
| AU (1) | AU2012332931B2 (enExample) |
| BR (1) | BR112014010563B1 (enExample) |
| CA (1) | CA2853454C (enExample) |
| ES (1) | ES2629690T3 (enExample) |
| IL (1) | IL232234A0 (enExample) |
| MX (1) | MX347191B (enExample) |
| PL (1) | PL2776432T3 (enExample) |
| RU (1) | RU2674017C2 (enExample) |
| WO (1) | WO2013066684A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011079274A1 (en) * | 2009-12-23 | 2011-06-30 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| WO2012145617A2 (en) * | 2011-04-22 | 2012-10-26 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| BR112014010563B1 (pt) | 2011-11-04 | 2021-01-12 | Jasco Pharmaceuticals, LLC | compostos inibidores da aminopirimidina quinase |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| TWI662030B (zh) | 2013-01-15 | 2019-06-11 | 英塞特控股公司 | 適用作ｐｉｍ激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物 |
| US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| RS62728B1 (sr) | 2015-08-04 | 2022-01-31 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivat pirazol pirimidina i njegove upotrebe |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| WO2018142393A1 (en) | 2017-02-01 | 2018-08-09 | Yissum Research Development Company Of The Hebrew | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| CN117567338A (zh) | 2019-10-09 | 2024-02-20 | 拜耳公司 | 作为农药的新的杂芳基三唑化合物 |
| IL328905A (en) * | 2023-12-21 | 2026-08-01 | Glaxosmithkline Intellectual Property No 4 Ltd | Chemical compounds and their uses |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1045776C (zh) * | 1994-03-28 | 1999-10-20 | 日产化学工业株式会社 | 吡啶环取代的噻唑烷和噁唑烷以及它们作为降血糖药的用途 |
| CN101052640A (zh) * | 2004-09-03 | 2007-10-10 | 应用研究系统Ars股份公司 | 吡啶亚甲基唑烷酮类及其作为磷酸肌醇抑制剂的用途 |
| WO2009064486A2 (en) * | 2007-11-15 | 2009-05-22 | Musc Foundation For Research Development | Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
| WO2010148351A1 (en) * | 2009-06-18 | 2010-12-23 | Cylene Pharmaceuticals, Inc. | Rhodanines and related heterocycles as kinase inhibitors |
| WO2011079274A1 (en) * | 2009-12-23 | 2011-06-30 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW245716B (enExample) | 1992-12-28 | 1995-04-21 | Takeda Pharm Industry Co | |
| US5955481A (en) | 1994-03-28 | 1999-09-21 | Nissan Chemical Industries, Ltd. | Pyridine type thiazolidines |
| WO1996012719A1 (en) | 1994-10-20 | 1996-05-02 | Nippon Chemiphar Co., Ltd. | Quinoline derivative |
| EP1758895A1 (en) | 2004-06-17 | 2007-03-07 | Wyeth a Corporation of the State of Delaware | Gonadotropin releasing hormone receptor antagonists |
| MX2007004302A (es) | 2004-10-12 | 2007-06-07 | Applied Research Systems | Inhibidores de pi3 cinasa gamma para el tratamiento de anemia. |
| EP1916249A1 (en) | 2006-10-10 | 2008-04-30 | LEK Pharmaceuticals D.D. | 3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(thio)oxo-2-(thio)oxo-azolidin-5-ylidene derivatives as antibacterial agents |
| US8252823B2 (en) | 2008-01-28 | 2012-08-28 | New York University | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof |
| EP2350051A4 (en) | 2008-10-29 | 2012-05-30 | Sirtris Pharmaceuticals Inc | PYRIDINE, BICYCLIC PYRIDINE AND ITS ANALOGS AS SIRTUINE MODULATORS |
| WO2012145617A2 (en) * | 2011-04-22 | 2012-10-26 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| BR112014010563B1 (pt) | 2011-11-04 | 2021-01-12 | Jasco Pharmaceuticals, LLC | compostos inibidores da aminopirimidina quinase |
-
2012
- 2012-10-24 BR BR112014010563-4A patent/BR112014010563B1/pt not_active IP Right Cessation
- 2012-10-24 WO PCT/US2012/061597 patent/WO2013066684A1/en not_active Ceased
- 2012-10-24 ES ES12780393.0T patent/ES2629690T3/es active Active
- 2012-10-24 AU AU2012332931A patent/AU2012332931B2/en active Active
- 2012-10-24 KR KR1020147014718A patent/KR101990605B1/ko not_active Expired - Fee Related
- 2012-10-24 CA CA2853454A patent/CA2853454C/en active Active
- 2012-10-24 MX MX2014005052A patent/MX347191B/es active IP Right Grant
- 2012-10-24 EP EP12780393.0A patent/EP2776432B1/en active Active
- 2012-10-24 JP JP2014539984A patent/JP6215832B2/ja not_active Expired - Fee Related
- 2012-10-24 RU RU2014122344A patent/RU2674017C2/ru active
- 2012-10-24 CN CN201280053781.XA patent/CN104011046B/zh not_active Expired - Fee Related
- 2012-10-24 PL PL12780393T patent/PL2776432T3/pl unknown
- 2012-10-24 US US13/659,343 patent/US8927525B2/en active Active
-
2014
- 2014-04-24 IL IL232234A patent/IL232234A0/en active IP Right Grant
- 2014-12-19 US US14/577,079 patent/US9629840B2/en active Active
-
2016
- 2016-12-09 US US15/374,013 patent/US10336743B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1045776C (zh) * | 1994-03-28 | 1999-10-20 | 日产化学工业株式会社 | 吡啶环取代的噻唑烷和噁唑烷以及它们作为降血糖药的用途 |
| CN101052640A (zh) * | 2004-09-03 | 2007-10-10 | 应用研究系统Ars股份公司 | 吡啶亚甲基唑烷酮类及其作为磷酸肌醇抑制剂的用途 |
| WO2009064486A2 (en) * | 2007-11-15 | 2009-05-22 | Musc Foundation For Research Development | Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
| WO2010148351A1 (en) * | 2009-06-18 | 2010-12-23 | Cylene Pharmaceuticals, Inc. | Rhodanines and related heterocycles as kinase inhibitors |
| WO2011079274A1 (en) * | 2009-12-23 | 2011-06-30 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| 4,6-二芳基-2-氨基嘧啶类衍生物的合成与生物活性;江银枝，等;《应用化学》;20110228;第28卷(第2期);第209-213页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150202205A1 (en) | 2015-07-23 |
| MX2014005052A (es) | 2015-03-19 |
| CA2853454C (en) | 2020-01-21 |
| JP6215832B2 (ja) | 2017-10-18 |
| ES2629690T3 (es) | 2017-08-14 |
| EP2776432B1 (en) | 2017-03-29 |
| RU2674017C2 (ru) | 2018-12-04 |
| US10336743B2 (en) | 2019-07-02 |
| AU2012332931B2 (en) | 2017-08-03 |
| RU2014122344A (ru) | 2015-12-10 |
| US20170247367A1 (en) | 2017-08-31 |
| IL232234A0 (en) | 2014-06-30 |
| MX347191B (es) | 2017-04-19 |
| PL2776432T3 (pl) | 2017-10-31 |
| WO2013066684A1 (en) | 2013-05-10 |
| KR101990605B1 (ko) | 2019-06-18 |
| KR20140098105A (ko) | 2014-08-07 |
| BR112014010563A2 (pt) | 2017-04-25 |
| US8927525B2 (en) | 2015-01-06 |
| CN104011046A (zh) | 2014-08-27 |
| EP2776432A1 (en) | 2014-09-17 |
| AU2012332931A1 (en) | 2014-06-12 |
| US9629840B2 (en) | 2017-04-25 |
| BR112014010563B1 (pt) | 2021-01-12 |
| JP2015501782A (ja) | 2015-01-19 |
| CA2853454A1 (en) | 2013-05-10 |
| US20130310342A1 (en) | 2013-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104011046A (zh) | 氨基嘧啶激酶抑制剂 | |
| CN102884062B (zh) | 氨基嘧啶激酶抑制剂 | |
| US8901145B2 (en) | Aminopyrimidine kinase inhibitors | |
| US9073903B2 (en) | Imidazole-2,4-dione inhibitors of casein kinase 1 | |
| JP6858252B2 (ja) | ラパマイシンシグナル伝達経路阻害剤のメカニズム標的、及びその治療応用 | |
| US11161823B2 (en) | Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170503 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |